New Zealand markets closed

Brickell Biotech, Inc. (BBI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.5700-0.4100 (-10.30%)
At close: 04:00PM EDT
3.5800 +0.01 (+0.28%)
Pre-market: 04:06AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.9800
Open3.8600
Bid0.0000 x 1100
Ask0.0000 x 800
Day's range3.5100 - 3.9200
52-week range3.5100 - 37.8000
Volume340,230
Avg. volume225,163
Market cap9.474M
Beta (5Y monthly)0.41
PE ratio (TTM)N/A
EPS (TTM)-0.4200
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est48.75
  • GlobeNewswire

    Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

    BOULDER, Colo., July 06, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that its management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2022, being held in New

  • GlobeNewswire

    Brickell Biotech Announces 1-For-45 Reverse Stock Split

    Common stock will begin trading on a split-adjusted basis on July 5, 2022BOULDER, Colo., July 01, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that at the special meeting of stockholders held on June 30, 2022,

  • GlobeNewswire

    Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

    – BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from the SAD and MAD parts of the Phase 1 study expected to be announced by early 2023 – BOULDER, Colo., May 19, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovati